• Berberrubine Modulates Urate Transporters and JAK2/STAT3 in

  2026-07-28

  This study demonstrates that berberrubine, a major metabolite of berberine, significantly attenuates hyperuricemia in mice by regulating urate transporter expression and suppressing the JAK2/STAT3 inflammatory pathway. These findings highlight key mechanistic advances for metabolic and inflammation-related disease models.

• BODIPY 581/591 C11: Advanced Lipid Peroxidation Imaging in C

  2026-07-28

  Explore how BODIPY 581/591 C11, a ratiometric fluorescent probe, enables cutting-edge lipid peroxidation detection in cardiovascular oxidative stress research—offering methodological depth and assay guidance beyond standard protocols.

• Cy3 NHS ester (non-sulfonated): Protocol and Troubleshooting

  2026-07-27

  Cy3 NHS ester (non-sulfonated) enables sensitive fluorescent labeling of amino groups in proteins, peptides, and oligonucleotides for biomedical imaging and analytical workflows. It is best suited for protocols where organic co-solvents are tolerated, but is not appropriate for strictly aqueous labeling or for applications requiring long-term storage of dye solutions.

• Wnt-C59: Precision PORCN Inhibitor Workflows in Cancer Biolo

  2026-07-27

  Wnt-C59 delivers unmatched selectivity for PORCN, enabling robust, reproducible inhibition of Wnt secretion in cancer and regenerative research. This guide distills proven workflows, advanced assay strategies, and troubleshooting tips—bridging bench findings with practical application.

• Bifendate (DDB): Advanced CYP3A4 Modulation in Hepatoprotect

  2026-07-26

  Explore how Bifendate (DDB) uniquely modulates CYP3A4 activity for hepatoprotection, with deep mechanistic insights and practical guidance for translational research. This article provides a distinct, evidence-driven perspective on DDB's autophagy inhibition and clinical relevance.

• Bardoxolone methyl: Mechanisms and Evidence for Redox Modula

  2026-07-25

  Bardoxolone methyl (CDDO methyl ester) is a potent modulator of the Nrf2 signaling pathway and an inhibitor of NF-kB, with established effects in oxidative stress and inflammation research. Its dual mechanism supports renoprotection, anti-leukemic activity, and tumor suppression, but clinical use is limited by cardiac adverse events. This article synthesizes atomic, verifiable findings relevant for translational workflows.

• Cyclopamine as a Hedgehog Pathway Inhibitor: Integrative Ins

  2026-07-24

  Explore Cyclopamine, a potent Hedgehog signaling inhibitor, and its pivotal role in cancer research, teratogenicity studies, and developmental biology. This article offers an advanced synthesis of mechanistic science, assay design, and emerging epigenetic perspectives beyond typical overviews.

• Idoxuridine as a Precision Tool: Disrupting Viral DNA Synthe

  2026-07-24

  Explore the profound utility of Idoxuridine as a viral DNA synthesis inhibitor and its strategic application in cutting-edge antiviral research. This article delivers a deeper, practical analysis of Idoxuridine’s mechanism, stability, and assay optimization for scientific investigators.

• Virus-Mimicking Nanoparticles Enable Extrahepatic IL-12 mRNA

  2026-07-23

  The reference study introduces a self-assembling enveloped virus-mimicking particle (EVMP) for targeted, extrahepatic mRNA delivery, overcoming the hepatic tropism of conventional lipid-based systems. This innovation demonstrates efficient and safe delivery of IL-12 mRNA to lung tissues, with significant implications for immunotherapy research and the development of programmable mRNA nanocarriers.

• BIIE 0246: Unveiling Y2R Antagonism for Adipose-Neural Axis

  2026-07-23

  Explore the unique capabilities of BIIE 0246, a potent neuropeptide Y Y2 receptor antagonist, in decoding adipose-neural axis mechanisms. This article offers an advanced, evidence-based analysis for neuroscience and cardiometabolic research.

• In Vitro Inhibitors of Monkeypox: Mubritinib’s Emerging Role

  2026-07-22

  Chiem et al. systematically identified compounds with in vitro anti-monkeypox activity, highlighting Mubritinib (TAK 165) among others as a potent inhibitor of both vaccinia and monkeypox viruses. This work expands the potential applications of mitochondrial complex I inhibitors in antiviral research and underscores the importance of drug repurposing for orthopoxvirus outbreaks.

• Entecavir (BMS200475): Applied Workflows for HBV Inhibition

  2026-07-22

  Entecavir stands out as a potent, selective inhibitor in chronic hepatitis B virus research, especially for tackling lamivudine-resistant strains and decompensated liver disease. This article delivers actionable protocol enhancements, real-world troubleshooting, and evidence-driven insights for maximizing assay reproducibility and translational impact.

• PDK4-IN-1 Hydrochloride: Reliable Modulation for Cell Viabil

  2026-07-21

  This article addresses common experimental challenges in cell viability and metabolic modulation assays, demonstrating how PDK4-IN-1 hydrochloride (SKU C8760) advances reproducibility and sensitivity for biomedical researchers. Drawing on peer-reviewed evidence and practical laboratory scenarios, it offers actionable guidance and protocol parameters for integrating this selective pyruvate dehydrogenase kinase 4 inhibitor into in vitro metabolism studies.

• Oral mSWI/SNF ATPase Degrader and Resistance in Prostate Can

  2026-07-21

  This study introduces AU-24118, the first orally bioavailable PROTAC degrader targeting mSWI/SNF ATPases in prostate cancer, showing robust antitumor activity and uncovering key mechanisms of acquired drug resistance. Notably, resistance mediated by ABCB1 overexpression can be reversed by zosuquidar, highlighting actionable strategies for overcoming multidrug resistance in advanced cancers.

• CTOP in Neuropharmacology: Precision μ-Opioid Receptor Antag

  2026-07-20

  CTOP enables researchers to dissect μ-opioid receptor-mediated signaling with unmatched selectivity, driving forward experimental pain and neuropharmacology studies. Leveraging its competitive antagonism and robust solubility, CTOP empowers rigorous investigation of opioid-induced hypersensitivity and tolerance pathways.

454 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page